Therapeutic potential of mesenchymal stem cells in acute kidney injury is affected by administration timing
Xiaoyan Liu, Jieru Cai, Xiaoyan Jiao, Xiaofang Yu, and Xiaoqiang Ding

Division of Nephrology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

Acta Biochim Biophys Sin 2017, 49: 338–348; doi: 10.1093/abbs/gmx016

Mesenchymal stem cell (MSC) transplantation is a promising therapy for acute kidney injury; however, the efficacy is limited due to poor survival after transplantation. In this study, we investigated how MSC transplantation timing affected the survival and therapeutic potential of MSCs in the kidney ischemia–reperfusion (I/R) injury model. After kidney I/R injury, the inflammatory process and tissue damage were characterized over 1 week post-I/R, we found that inflammation peaked at 12–24 h post-I/R (h.p.i.), and urine neutrophil gelatinase-associated lipocalin (NGAL) measurements correlated highly with measures of inflammation. We cultured MSCs with supernatants from I/R injured kidney tissue homogenates collected at different time points and found that kidney homogenates from 12 and 24 h.p.i. were most toxic to MSCs, whereas homogenates from 1 h.p.i. were not as cytotoxic as those from 12 and 24 h.p.i. Compared with MSCs administered at 12, or 24 h.p.i., cells administered immediately after ischemia or 1 h.p.i. yielded the highest renoprotective and anti-inflammatory effects. Our findings indicate that MSC treatment for acute kidney injury is most effective when applied prior to the development of a potent inflammatory microenvironment, and urine NGAL may be helpful for detecting inflammation and selecting MSC transplantation timing in I/R kidney injury.

Renoprotective effects of MSC therapy when applied at different post-I/R time points

阅读原文: http://www.abbs.org.cn/arts.asp?id=4140

获取全文: abbs@sibs.ac.cn

相关论文:

1 Pathophysiology of ischemic acute kidney injury

2 Mesenchymal Stem Cell-Derived Microvesicles Protect Against Acute Tubular Injury

3 Cellular pathophysiology of ischemic acute kidney injury

4 Therapeutic potential of mesenchymal stem cell-derived microvesicles

5 Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial

6 Microvesicles Derived from Mesenchymal Stem Cells Enhance Survival in a Lethal Model of Acute Kidney Injury

7 Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog

8 Clinical Trials With Mesenchymal Stem Cells: An Update